(PR-inside.com) Report Highlights Efficacy of New Antibody Therapy in Advanced Colorectal Cancer
More...
AUSTIN, Texas, Jan. 17, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announced the publication of results from its pivotal phase 3 trial of the Company's lead monoclonal antibody therapy. The results were published in*The Lancet Oncology*in an article titled, "MABp1 as a Novel Antibody Treatment for Advanced Colorectal Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study."*The article is now available online.
"The findings indicate what .. More...